GURUFOCUS.COM » STOCK LIST » USA » NAS » Moderna Inc (NAS:MRNA) » Definitions » Debt-to-Equity
Switch to:

Moderna (NAS:MRNA) Debt-to-Equity

: 0.06 (As of Mar. 2023)
View and export this data going back to 2018. Start your Free Trial

Moderna's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $181 Mil. Moderna's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $927 Mil. Moderna's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $18,863 Mil. Moderna's debt to equity for the quarter that ended in Mar. 2023 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Moderna's Debt-to-Equity or its related term are showing as below:

MRNA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02   Med: 0.06   Max: 0.11
Current: 0.06

During the past 7 years, the highest Debt-to-Equity Ratio of Moderna was 0.11. The lowest was 0.02. And the median was 0.06.

MRNA's Debt-to-Equity is ranked better than
68.19% of 1097 companies
in the Biotechnology industry
Industry Median: 0.14 vs MRNA: 0.06

Moderna Debt-to-Equity Historical Data

The historical data trend for Moderna's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Equity
Premium Member Only Premium Member Only 0.02 0.11 0.09 0.07 0.06

Moderna Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.05 0.07 0.06 0.06

Competitive Comparison

For the Biotechnology subindustry, Moderna's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Moderna Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Moderna's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Moderna's Debt-to-Equity falls in comparison to its industry or sector. The grey bar indicates the Debt-to-Equity's extreme value range as defined by GuruFocus.



Moderna Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Moderna's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Moderna's Debt to Equity Ratio for the quarter that ended in Mar. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moderna  (NAS:MRNA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Moderna Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Moderna's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (NAS:MRNA) Business Description

Moderna logo
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
James M Mock officer: Chief Financial Officer 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Arpa Garay officer: Chief Commercial Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Jorge M Gomez officer: See Remarks C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Burton officer: Chief Medical Officer 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Shannon Thyme Klinger officer: Chief Legal Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth E Tallett director 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
David W Meline officer: Chief Financial Officer 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Sandra Horning director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Paul Sagan director AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Israel Ruiz director C/O FORTIVE CORPORATION, 6920 SEAWAY BOULEVARD, EVERETT WA 98203
Tal Zvi Zaks officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115

Moderna (NAS:MRNA) Headlines

Other Sources

Is Moderna (MRNA) a High Growth Stock?

By Yahoo Finance 2023-01-30